TW200716610A - Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester - Google Patents
Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl esterInfo
- Publication number
- TW200716610A TW200716610A TW095114916A TW95114916A TW200716610A TW 200716610 A TW200716610 A TW 200716610A TW 095114916 A TW095114916 A TW 095114916A TW 95114916 A TW95114916 A TW 95114916A TW 200716610 A TW200716610 A TW 200716610A
- Authority
- TW
- Taiwan
- Prior art keywords
- methyl
- hexyloxycarbonylamino
- phenylamino
- imino
- pyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005020002A DE102005020002A1 (de) | 2005-04-27 | 2005-04-27 | Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200716610A true TW200716610A (en) | 2007-05-01 |
Family
ID=36952435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095114916A TW200716610A (en) | 2005-04-27 | 2006-04-26 | Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
Country Status (10)
Country | Link |
---|---|
US (2) | US20060247278A1 (zh) |
EP (1) | EP1877395A2 (zh) |
JP (1) | JP2008539199A (zh) |
AR (1) | AR054261A1 (zh) |
CA (1) | CA2606090A1 (zh) |
DE (1) | DE102005020002A1 (zh) |
PE (1) | PE20061321A1 (zh) |
TW (1) | TW200716610A (zh) |
UY (1) | UY29493A1 (zh) |
WO (1) | WO2006114415A2 (zh) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
DE10339862A1 (de) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
US20100087488A1 (en) * | 2006-10-10 | 2010-04-08 | Boehringer Ingelheim International Gmgh | Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
NZ586868A (en) * | 2008-03-28 | 2012-02-24 | Boehringer Ingelheim Int | Process for preparing orally administered dabigatran formulations |
CN102099012A (zh) * | 2008-07-14 | 2011-06-15 | 贝林格尔.英格海姆国际有限公司 | 制备含有达比加群的药物制剂的方法 |
BRPI0921479A2 (pt) | 2008-11-11 | 2016-01-12 | Boehringer Ingelheim Int | método para tratamento ou prevenção de trombose usando etexilato de dabigatran ou um sal do mesmo com aprimorado perfil de segurança em relação à terapia convencional com varfarina |
US9063163B2 (en) * | 2009-02-02 | 2015-06-23 | Boehringer Ingelheim International Gmbh | Lyophilised dabigatran |
HUP1000069A2 (en) | 2010-02-02 | 2012-05-02 | Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag | New salts for the preparation of pharmaceutical composition |
US20130149346A1 (en) | 2010-03-08 | 2013-06-13 | ratiopharm GmbH Graf-Arco-Strasse 3 | Dabigatran etexilate-containing pharmaceutical composition |
CN103025715A (zh) | 2010-07-09 | 2013-04-03 | 埃斯特维化学股份有限公司 | 用于制备凝血酶特异性抑制剂的中间体和方法 |
EP2937343A1 (en) | 2010-07-09 | 2015-10-28 | Esteve Química, S.A. | Process of preparing a thrombin specific inhibitor |
EP2603503B1 (en) | 2010-09-27 | 2015-08-05 | ratiopharm GmbH | Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof |
WO2012162492A1 (en) | 2011-05-24 | 2012-11-29 | Teva Pharmaceutical Industries Ltd. | Compressed core comprising organic acids for a pharmaceutical composition |
EP2806858A1 (en) * | 2012-01-24 | 2014-12-03 | Boehringer Ingelheim International Gmbh | Novel orally administered dabigatran formulation |
CN103304539A (zh) * | 2012-03-07 | 2013-09-18 | 天津药物研究院 | 达比加群酯苹果酸盐及其制备方法和应用 |
WO2013144971A1 (en) | 2012-03-27 | 2013-10-03 | Cadila Healthcare Limited | New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them |
US9273030B2 (en) | 2012-04-02 | 2016-03-01 | Msn Laboratories Private Limited | Process for the preparation of benzimidazole derivatives and salts thereof |
US20150225370A1 (en) | 2012-09-28 | 2015-08-13 | Ranbaxy Laboratories Limited | Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof |
IN2015DN02616A (zh) | 2012-09-28 | 2015-09-18 | Ranbaxy Lab Ltd | |
WO2014060561A1 (en) | 2012-10-19 | 2014-04-24 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Oral pharmaceutical formulations comprising dabigatran |
EP2722033A1 (en) | 2012-10-19 | 2014-04-23 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical Compositions of Dabigatran Free Base |
CN103864756B (zh) * | 2012-12-11 | 2018-06-15 | 四川海思科制药有限公司 | 丁二磺酸达比加群酯及其制备方法和用途 |
WO2014178017A1 (en) | 2013-04-30 | 2014-11-06 | Ranbaxy Laboratories Limited | Dabigatran etexilate impurity, process of its preparation, and its use as a reference standard |
WO2015124764A1 (en) | 2014-02-24 | 2015-08-27 | Erregierre S.P.A. | Synthesis process of dabigatran etexilate mesylate, intermediates of the process and novel polymorph of dabigatran etexilate |
CN104892574A (zh) * | 2014-03-04 | 2015-09-09 | 浙江海正药业股份有限公司 | 达比加群酯甲磺酸盐的晶型及其制备方法和用途 |
CN108947966A (zh) * | 2014-04-04 | 2018-12-07 | 江苏天士力帝益药业有限公司 | 达比加群酯甲磺酸盐新晶型及其制备方法 |
US10130618B2 (en) | 2014-04-11 | 2018-11-20 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical combinations of dabigatran and proton pump inhibitors |
EP2929884A1 (en) | 2014-04-11 | 2015-10-14 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical combinations of dabigatran and h2-receptor antagonists |
WO2017013106A1 (en) | 2015-07-20 | 2017-01-26 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical formulations of dabigatran free base |
TR201606697A2 (tr) | 2016-05-20 | 2017-12-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabi̇gatranin yeni̇ oral farmasöti̇k formülasyonlari |
EP3332771A1 (en) | 2016-12-07 | 2018-06-13 | Sanovel Ilac Sanayi ve Ticaret A.S. | Multilayered tablet compositions of dabigatran |
TR201617984A2 (tr) | 2016-12-07 | 2018-06-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabi̇gatranin farmasöti̇k kompozi̇syonlari |
TR201722186A2 (tr) | 2017-12-27 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabi̇gatranin farmasöti̇k kompozi̇syonlari |
TR201722323A2 (tr) | 2017-12-27 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari |
TR201722630A2 (zh) | 2017-12-28 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087380A (en) * | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
PE121699A1 (es) * | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
US6414008B1 (en) * | 1997-04-29 | 2002-07-02 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions |
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
DE10235639A1 (de) * | 2002-08-02 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE10337697A1 (de) * | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze |
DE10339862A1 (de) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
EP1609784A1 (de) * | 2004-06-25 | 2005-12-28 | Boehringer Ingelheim Pharma GmbH & Co.KG | Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen |
-
2005
- 2005-04-27 DE DE102005020002A patent/DE102005020002A1/de not_active Withdrawn
-
2006
- 2006-04-24 UY UY29493A patent/UY29493A1/es not_active Application Discontinuation
- 2006-04-25 EP EP06754844A patent/EP1877395A2/de not_active Withdrawn
- 2006-04-25 PE PE2006000434A patent/PE20061321A1/es not_active Application Discontinuation
- 2006-04-25 WO PCT/EP2006/061820 patent/WO2006114415A2/de not_active Application Discontinuation
- 2006-04-25 CA CA002606090A patent/CA2606090A1/en not_active Abandoned
- 2006-04-25 JP JP2008508213A patent/JP2008539199A/ja active Pending
- 2006-04-26 AR AR20060101660A patent/AR054261A1/es not_active Application Discontinuation
- 2006-04-26 US US11/380,351 patent/US20060247278A1/en not_active Abandoned
- 2006-04-26 TW TW095114916A patent/TW200716610A/zh unknown
-
2008
- 2008-10-08 US US12/247,678 patent/US20090042948A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE102005020002A1 (de) | 2006-11-02 |
UY29493A1 (es) | 2006-11-30 |
US20060247278A1 (en) | 2006-11-02 |
JP2008539199A (ja) | 2008-11-13 |
PE20061321A1 (es) | 2007-01-15 |
WO2006114415A2 (de) | 2006-11-02 |
WO2006114415A3 (de) | 2007-01-25 |
CA2606090A1 (en) | 2006-11-02 |
US20090042948A1 (en) | 2009-02-12 |
EP1877395A2 (de) | 2008-01-16 |
AR054261A1 (es) | 2007-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200716610A (en) | Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester | |
TW200716107A (en) | Polymorphs of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester | |
WO2008059029A3 (en) | New polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate | |
ME00340B (me) | ETIL 3-[(2-{[4-(HEKSILOKSIKARBONILAMINO-IMINO-METIL)-FENILAMINO]-METIL}-l-METIL-IH-BENZIMIDAZOL-5-KARBONIL)-PIRIDIN-2-IL-AMINO]-PROPIONAT-METANSULFONAT I NJEGOVA PRIMJENA KAO LIJEKA | |
CY1108218T1 (el) | Δισκιο που περιεχει 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλο}-1 -μεθυλο-1 η-βενζιμιδαζολο5-καρβονυλο)-πυριδιν-2-υλ-αμινο] προπιονικο αιθυλεστερα | |
MY143734A (en) | Administration form for the oral application of 3-[(2-<[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl>-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof | |
WO2012001156A3 (en) | Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts | |
WO2009041705A3 (en) | 5-membered heterocyclic compounds as proton pump inhibitors | |
ME01239B (me) | Čvrsti preparat koji sadrži alogliptin i pioglitazon | |
MX367154B (es) | Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico. | |
HK1158627A1 (en) | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-h- pyrrole derivatives as acid secretion inhibitors | |
MX2007012443A (es) | Formulaciones farmaceuticas orales que comprenden acido fenofibrico y/o sus sales. | |
WO2008114800A8 (en) | Solid preparation comprising 2- [ [6- [ (3r) -3-amino-1-piperidinyl] -3, 4-dihydro-3-methyl-2, 4-dioxo-1 (2h) -pyrimidinyl] methyl] -4-fluorobenzonitrile | |
TN2012000031A1 (en) | Tablet | |
WO2008084067A3 (en) | Pharmaceutically active dihydrobenzofurane-substituted benzimidazole derivatives | |
TH102393A (th) | การดำเนินการให้ของสารยับยั้งไดเปปติดิล เปปติเดส | |
TH102393B (th) | การดำเนินการให้ของสารยับยั้งไดเปปติดิล เปปติเดส | |
WO2008017466A8 (en) | Pharmaceutically active tetrahydroisoquinoline-substituted benzimidazole derivatives |